Monoamine oxidase B

Monoamine oxidase B Molekülinformation

Englischer Name	Monoamine oxidase B	Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	13	Target-Alias	EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Monoamine oxidase B
Target-Alias	EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4
Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	13
Höchste Forschungs- und Entwicklungsphase	Approved

Monoamine oxidase B Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
MAB-H5547	Human	InsectCells	Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme)				In den Warenkorb legen

Gesamtmenge1

Monoamine oxidase B Molekülhintergrund

Monoamine Oxidase Type B (MAOB) is an enzyme located in the outer mitochondrial membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the breakdown of dopamine in the brain. MAOB inhibitors, that reduces dopamine turnover, are in clinical use for the treatment of Parkinson's disease (PD).

Monoamine oxidase B Molekülalias

MAOB, MAO-B,Monoamine Oxidase B,Monoamine oxidase type B

Lizenzierungszusammenarbeit

Projektname	Arzneimitteltyp	Therapiegebiet	Indikationen	Stufe	Rechtsgebiet
Reversible MAOB Inhibitor	Small molecule	Neurological disease	Parkinson's disease	Phase I	Global

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate	P2B-001	Phase 3 Clinical	Pharma Two B Ltd	Parkinson Disease	Details
Vafidemstat	ORY-2001	Phase 2 Clinical	Oryzon Genomics Sa	Alzheimer Disease; Borderline Personality Disorder; Kabuki syndrome; Schizophrenia	Details
J-147	J-147	Phase 2 Clinical	Salk Institute	Alzheimer Disease; Ischemic Stroke	Details
Tisolagiline	KDS2010; KDS-2010	Phase 2 Clinical	NeuroBiogen	Alzheimer Disease; Cognitive Dysfunction; Dementia; Obesity; Overweight	Details
Rasagiline transdermal patch (Teikoku Pharma)		Phase 1 Clinical	Teikoku Pharma	Parkinson Disease	Details
SKL-PD	YKP-10461; SKL-PD	Phase 1 Clinical	SK Biopharmaceuticals Co Ltd	Parkinson Disease	Details
18F-FCOB04	18F-FCOB04; 18F-FCOB-04	Phase 1 Clinical	Peking Union Medical College Hospital	Neurodegenerative Diseases	Details
LNTH-2511		Phase 1 Clinical	Lantheus Holdings Inc	Neuroinflammatory Diseases	Details
Pramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma)		Phase 1 Clinical	Zhejiang Jingxin Pharmaceutical Co Ltd	Parkinson Disease	Details
Rasagiline Mesylate Sublingual membrane(Shanghai Shangyao Zhongxi Pharma)		Phase 1 Clinical	Shanghai Shangyao Zhongxi Pharmaceutical Co Ltd	Parkinson Disease	Details
Rasagiline Mesylate Transdermal Patch(world leader)		Phase 1 Clinical	Guizhou Shiling Pharmaceutical Co Ltd, Shanghai World Ling Pharmaceutical Co Ltd	Parkinson Disease	Details
HEC-122505MsOH	HEC-122505MsOH; HEC-122505-MsOH; HEC122505MsOH	Phase 1 Clinical	Guangdong Dongyangguang Pharmaceutical Co Ltd	Parkinson Disease	Details
18F-SMBT-1	18F-SMBT-1; 18-F-SMBT-1	Clinical	Tohoku University		Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Rasagiline Mesylate	Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012	Approved	Teva	Azilect, Agilect	EU	Parkinson Disease	Teva Bv	2005-02-21	Alzheimer Disease; Dementia; Multiple System Atrophy; Parkinson Disease; REM Sleep Behavior Disorder; Restless Legs Syndrome; Supranuclear Palsy, Progressive; Synucleinopathies	Details
Selegiline Hydrochloride	FPF-1100; E-250 (free base)	Approved	Sanofi	FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline	Mainland China	Parkinson Disease	Chinoin Pharmaceutical And Chemical Works Co Ltd	1989-06-05	Amphetamine-Related Disorders; Borderline Personality Disorder; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder, Major; HIV Infections; Marijuana Abuse; Parkinson Disease; Schizophrenia; Tobacco Use Cessation; Tobacco Use Disorder	Details
Safinamide Mesylate	PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125; PNU-151774; FCE-26743	Approved	Newron Pharmaceutical	Xadago, Equfina	EU	Parkinson Disease	Zambon Spa	2015-02-23	Dyskinesia, Drug-Induced; Hepatic Insufficiency; Multiple System Atrophy; Parkinson Disease; Renal Insufficiency	Details